AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04055337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flap sliding
Description: All subjects underwent the flap sliding technique, which was performed at the Alforsan Eye Centre in Assiut, Egypt. Prior to surgery, all subjects underwent corneal imaging with anterior segment optical coherence tomography to confirm the presence of striae. All surgical procedures were performed by the same surgeon 1 or 2 days following LASIK.~Subjects were administered a topical anesthetic. Striae location and orientation were then determined after drying the corneal surface with a cellulose sponge. The sponge was used to push the LASIK flap over the stromal bed in a direction that was perpendicular to the striae. The flap was pushed from the proximal side of the striae toward the flap edge. The ultimate goal was to move striae and put the flap into its proper place. Following surgery, OCT imaging was repeated.
Study NCT01396278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI
Study NCT01396278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate HFA MDI
Study NCT01396278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903 via Respimat inhaler
Study NCT02195245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: memsorb
Study NCT04910126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg q3w up to 2 years
Study NCT04910126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Description: adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles
Study NCT04910126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles
Study NCT02244034 — intervention group
Intervention type: PROCEDURE
Intervention: hypothermia
Study NCT04227639 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece trial
Description: T-piece trial will be performed for around 1 hour with a T-piece connected to the extremity of the endotracheal tube by simply disconnecting the patient from the ventilator and by providing additional oxygen (≤ 6 L/min)
Study NCT04227639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure-support trial
Description: Pressure-Support trial will be performed for around 1 hour without disconnecting the patient from the ventilator, by using a low level of pressure-support (PS 8 cm H2O) with a FiO2 ≤ 40% and without positive end-expiratory pressure (PEEP), while continuously monitoring the respiratory rate and tidal volume on the ventilator display.
Study NCT03203447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: suprachoroidal CLS-TA
Description: suprachoroidal injection of CLS-TA
Study NCT03203447 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: suprachoroidal sham
Description: sham suprachoroidal procedure
Study NCT03203447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis or Avastin
Description: IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
Study NCT03203447 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lucentis or Avastin
Description: IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
Study NCT03311152 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)
Description: The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.
Study NCT04513912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Participants will receive seltorexant over-encapsulated tablet orally.
Study NCT04513912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to Seltorexant
Description: Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
Study NCT04513912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: Participants will receive quetiapine XR capsule orally.
Study NCT04513912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo to Quetiapine XR
Description: Participants will receive placebo capsule matching to quetiapine XR orally.
Study NCT01705769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food-Centrally produced
Description: Ready to Use Therapeutic Food-Centrally produced by an Indian company.
Study NCT01705769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food-Locally produced
Description: Ready to Use Therapeutic Food prepared by the study team
Study NCT01705769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High energy and micronutrient rich foods
Description: High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
Study NCT03117569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glecaprevir (300mg)/pibrentasvir (120mg)
Description: glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
Study NCT03117569 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: glecaprevir (300mg)/pibrentasvir (120mg)
Description: glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
Study NCT01118247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uncemented primary total hip arthroplasty
Description: Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.
Study NCT01118247 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uncemented primary total hip arthroplasty
Description: Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.
Study NCT01449630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3031207
Description: Administered orally
Study NCT01449630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01449630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Administered orally
Study NCT01876706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift® System
Description: The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
Study NCT01390337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Oral Liquid
Study NCT01390337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: Intravenous Infusion
Study NCT01390337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Intravenous Infusion
Study NCT01709474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 6000 IU
Description: Subjects will receive 6,000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day. Note: Subjects weighing \<40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
Study NCT01709474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 400 IU
Description: Subjects will receive 400 IU/day of vitamin D3 daily by mouth.
Study NCT01244126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal fentanyl
Description: 2mcg/kg fentanyl IN
Study NCT01244126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine IM
Description: 0.1 mg/kg morphine IM for postop pain
Study NCT01244126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine
Description: 0.1 mg/kg morphine IV
Study NCT03713281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Multifocal etafilcon A with PVP
Description: Investigational
Study NCT02749513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study NCT02366780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pump
Description: Breast milk expression using manually or using an electric pump
Study NCT01716793 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ara-C
Description: * Intermediate dose during induction phase to remission.~* High-dose during consolidation phase in patients with favorable cytogenetics.
Study NCT01716793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Autologous transplantation
Description: * In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.~* In patients with other cytogenetics without HLA-Identical sibling.
Study NCT01716793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Allogeneic HLA-identical sibling transplantation
Description: * Patients without favorable or normal karyotype(and one course to CR).~* Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics.
Study NCT01716793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CD34+ selection
Description: In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
Study NCT04448223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-351
Description: Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day
Study NCT04448223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost+Dorzolmamide
Description: Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day
Study NCT03746093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Participants will consume a bottle of water (330 ml) every day for 12 weeks.
Study NCT03746093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-alcoholic beer
Description: Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
Study NCT02109042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blosozumab
Description: Administered subcutaneously
Study NCT00822874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prematuration culture
Description: The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos.
Study NCT00765648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicardipine intravenous
Description: nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
Study NCT00765648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
Study NCT02401386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Eight Brocades
Description: Patients received closely supervised, group-format EB program and practiced EB revised by Chinese Medicine Master Zhi-zheng Lu for one hour, twice weekly for 12 weeksmovements, a review of principles, and breathing techniques in EB. Participants will be asked to practice EB at home for at least 16 minutes each day which is how long it takes to complete an EB exercise, using an instructional Digital Video Disc. The program will be taught by experienced EB masters.
Study NCT00740493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: 18 months of warfarin therapy
Study NCT00740493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of warfarin
Description: 18 months of placebo of warfarin therapy
Study NCT03589534 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: home pregnancy test
Description: Each participant will use 4 different home pregnancy tests
Study NCT01386047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Clinical Prediction Rule (iCPR)
Description: Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
Study NCT01308593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvederm XC
Description: Filler
Study NCT01308593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox
Description: 26 units dosed one time
Study NCT01419106 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (A point of care ultrasound protocol)
Description: Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
Study NCT02398071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A water pressure threshold device (BreatheMAX)
Description: BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
Study NCT02398071 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: A water pressure threshold device (BreatheMAX)
Description: BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
Study NCT00881556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: 60 mcg/kg/day for 6 days
Study NCT00881556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV x 1 for 6 days
Study NCT00881556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 4 mg/kg/day IV divided BID for 4 days
Study NCT00881556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: 0.02-0.05 mg/kg for 5 days
Study NCT00881556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 20 mg/m2 IV for 5 days
Study NCT00881556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.03mg/kg/24 hours as continuous infusion for 4 days
Study NCT03597334 — intervention group
Intervention type: BEHAVIORAL
Intervention: aerosol therapy
Description: Aerosol inhalation therapy refers to a local administration method in which a drug is made into aerosol particles having a very small diameter and is inhaled by a patient and the drug directly acts on the airway
Study NCT00150462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered as an IV bolus dose
Study NCT00150462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally prior to carfilzomib
Study NCT05007288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restorative Eye Treatment (RET) cream
Description: RET cream will be applied topically to either the left of right eyelid once daily for 4 consecutive weeks.
Study NCT05007288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INhance with Trihex Technology
Description: INhance will be applied topically to both eyelids once daily for 10 consecutive days after the SOC blepharoplasty surgery.
Study NCT02298465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine ESWL
Description: ESWL to distal ureteric stone is performed in the supine position with the shockwave generator placed in the patient's buttock area. The aim is to direct the shockwaves through the greater and lesser sciatic foramina to reach the distal ureter.
Study NCT02298465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone ESWL
Description: ESWL to the distal ureteric stone is performed in the traditional prone position. The shockwave generator is placed on the patient's abdomen
Study NCT02298465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Lithotripsy (ESWL)
Description: The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
Study NCT02298465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Lithotripsy (ESWL)
Description: The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
Study NCT04480073 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Customized CAD-CAM Titanium Mesh (Y-xoss CBR® by Reoss -Filderstadt - Germany) for Guided Bone Regeneration of atrophic alveolar ridges
Description: Step one:1) exposure of atrophic areas; 2) bone harvesting from mandible or calvarium; 3) filling the meshes with a mixture of the autogenous bone and particulated xenograft in a 1:1 ratio; 4) stabilization of the mesh with titanium micro-screws.~A post-operative cone-beam computed tomography (CBCT) will be done in all patients to have a reference point for the following controls.~6 months later, patients are re-evaluated with a new CBCT to check bone volumes of the regenerated tissues and to plan implant placement.~Step two: 1) removal of the meshes; 2) preparation of implant sites (one of which will be randomly chosen to obtain a bone biopsy for histomorphometric analysis); 3) implant placement.~3 months later, implants will be uncovered and the prosthetic phases will start.~Patients will be recalled 3, 6, and 12 months later, to assess peri-implant hard and soft tissue conditions, the stability of the reconstructed bone, and the onset of implant-related complications.
Study NCT03468868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program for people with MS
Description: The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.
Study NCT03228693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy and/or triamcinolone injection
Description: Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.
Study NCT03228693 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Excisional Biopsy
Description: Complete excision of an earlobe keloid will be taken.
Study NCT03272048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lethal Means Counseling
Description: Lethal means counseling is broadly defined as clinician-initiated discussions that encourage an individual at risk for suicide to safely store his or her firearms. Examples in this domain include applying a gun lock, separating the gun from its ammunition, dismantling the firearm and keeping its components locked and/or separated, or safely transferring the firearm to a trusted loved one, friend, or police station until risk abates (Bryan, Stone, \& Rudd, 2011; Jin, Khazem, \& Anestis, 2016). Further, given that recent purchasers of firearms are at markedly increased risk of death by suicide (Wintemute, Parham, Beaumont, Wright, \& Drake, 1999), anticipatory counseling on firearm safety should also be considered for at-risk individuals who do not report currently owning or having access to a firearm, but who report prior firearm ownership/access or intentions of obtaining a firearm in the future (Harvard T.H. Chan School of Public Health, 2017).
Study NCT04365309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 100mg
Description: on the bases of standard treatment for the COVID-19, low-dose aspirin (100 mg/ day), orally，is added to.
Study NCT03049488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-RSVRGP084-00-VP
Description: VRC-RSVRGP084-00-VP is an investigational respiratory syncytial virus (RSV) vaccine.
Study NCT03049488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aluminum Hydroxide Suspension
Description: Aluminum Hydroxide Suspension, alum, is an adjuvant.
Study NCT00811668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP before SOMNOVentCR
Description: 4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment
Study NCT00811668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOMNOventCR before CPAP
Description: 4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment